Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Suresh S. Ramalingam(Emory University), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Gabriel Sica(Emory University), Ticiana Leal(University of Wisconsin Carbone Cancer Center), James L. Wade(American Society of Clinical Oncology), Charu Aggarwal(UPMC Hillman Cancer Center), Gordan Srkalović(Regional Cancer Center), Lynne I. Wagner(University of North Carolina at Chapel Hill), Bradley W. Lash(SUNY Upstate Medical University), Joseph W. Leach(Minnesota Oncology)
Cited by 10
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k